

5367.230-US
October 27, 2004

Application Number 10/730,215
Page 7 of 10

AMENDMENTS TO THE CLAIMS

The following Listing of Claims replaces all prior versions, and listings, of claims in this Application.

LISTING OF CLAIMS

1-3 (cancelled)

4. (presently amended) A method of promoting the treatment of intestinal cancer damage therapy in a patient comprising administering to the patient an effective amount of a pharmaceutically acceptable composition comprising (a) a non-naturally occurring polypeptide having an amino acid sequence according to the formula ~~X1-H-X2-D-G-S-F-S-D-E-M-N-T-X3-L-D-X4-L-A-X5-X6-D-F-I-N-W-L-X7-X8-T-K-I-T-D-X9-~~ His Xaa²-D-Asp Gly Ser Phe Ser Asp Glu Met Asn Thr Xaa³ Leu Asp Xaa⁴ Leu Ala Xaa⁵ Xaa⁶-D-Asp Phe Ile Asn Trp Leu Xaa⁷ Xaa⁸ Thr Lys Ile Thr Asp Xaa⁹ Xaa¹⁰ (SEQ ID NO:1), wherein Xaa² is Ala or Gly; Xaa³ is Ile or Val; Xaa⁴ is Asn, Ser or His; Xaa⁵ is Ala or Thr; Xaa⁶ is Arg or Lys; Xaa⁷ is Ile or Leu; Xaa⁸ is Gln or His; Xaa⁹ is OH, Lys, or Arg, and Xaa¹⁰ is Lys, Arg, or is missing and optionally further including an N-terminal positioned sequence selected from Asp Phe Pro Glu Glu Val Ala Ile Val Glu Glu Leu Gly Arg Arg (SEQ ID NO:2), Asp Phe Pro Glu Glu Val Thr Ile Val Glu Glu Leu Gly Arg Arg (SEQ ID NO:3), Asp Phe Pro Glu Glu Val Asn Ile Val Glu Glu Leu Arg Arg Arg (SEQ ID NO:4), or a fragment of any of SEQ ID NOS:2-4, and

(b) a pharmaceutically acceptable combination of (i) an isotonic agent, (ii) a buffer, and (iii) a preservative, a surfactant, or a combination of a surfactant and a preservative, wherein (I) ~~X1 is NH₂, DFPEEVAIVEELGRR (SEQ ID NO:2), DFPEEVTIVEELGRR (SEQ ID NO:3), DFPEEVNIVEELRRR (SEQ ID NO:4), or a fragment of any of SEQ ID NOS:2-4; X2 is Ala or Gly; X3 is Ile or Val; X4 is Asn, Ser, or His; X5 is Ala or Thr; X6 is Arg or Lys; X7 is Ile or Leu; X8 is Gln or His; and X9 is OH, Lys, Arg, Arg-Lys, Lys-Arg, Arg-Arg, or Lys-Lys and (II) the solubility~~

5367.230-US
October 27, 2004

Application Number 10/730,215
Page 8 of 10

of the peptide, stability of the peptide, or both is significantly greater than the solubility and/or stability of the peptide without the combination to the patient.

5. (presently amended) The method of claim 4, wherein Xaa² ~~X2~~ represents Gly.

6-9 (cancelled)

10. (presently amended) A method of promoting the treatment of ~~small bowel syndrome, Crohn's disease, ileitis, intestinal inflammation, gastric ulceration, duodenal ulceration, inflammatory bowel disease, or intestinal cancer damage~~ therapy in a patient comprising administering an effective amount of ~~the peptide of claim 6~~ a non-naturally occurring polypeptide having an amino acid sequence according to the formula His Xaa² ~~D~~ Asp Gly Ser Phe Ser Asp Glu Met Asn Thr Xaa³ Leu Asp Xaa⁴ Leu Ala Xaa⁵ Xaa⁶ ~~D~~ Asp Phe Ile Asn Trp Leu Xaa⁷ Xaa⁸ Thr Lys Ile Thr Asp Xaa⁹ Xaa¹⁰ (SEQ ID NO:1), wherein Xaa² is Ala or Gly; Xaa³ is Ile or Val; Xaa⁴ is Asn, Ser or His; Xaa⁵ is Ala or Thr; Xaa⁶ is Arg or Lys; Xaa⁷ is Ile or Leu; Xaa⁸ is Gln or His; Xaa⁹ is OH, Lys, or Arg, and Xaa¹⁰ is Lys, Arg, or is missing and optionally further including an N-terminal positioned sequence selected from Asp Phe Pro Glu Glu Val Ala Ile Val Glu Glu Leu Gly Arg Arg (SEQ ID NO:2), Asp Phe Pro Glu Glu Val Thr Ile Val Glu Glu Leu Gly Arg Arg (SEQ ID NO:3), Asp Phe Pro Glu Glu Val Asn Ile Val Glu Glu Leu Arg Arg Arg (SEQ ID NO:4), or a fragment of any of SEQ ID NOS:2-4 ~~X1-H-X2-D-G-S-F S-D-E-M-N-T-X3-L-D-X4-L-A-X5-X6-D-F-I-N-W-L-X7-X8-T-K-I-T-D-X9~~ (SEQ ID NO: 1), ~~wherein (I) X1 is NH2, DFPEEVAIVEELGRR (SEQ ID NO:2), DFPEEVTVIVEELGRR (SEQ ID NO:3), DFPEEVNIVEELRRR (SEQ ID NO:4), or a fragment of any of SEQ ID NOS:2-4; X2 is Ala or Gly; X3 is Ile or Val; X4 is Asn, Ser, or His; X5 is Ala or Thr; X6 is Arg or Lys; X7 is Ile or Leu; X8 is Gln or His; and X9 is OH, Lys, Arg, Arg-Lys, Lys-Arg, Arg-Arg, or Lys-Lys to the patient.~~

5367.230-US
October 27, 2004

Application Number 10/730,215
Page 9 of 10

11. (presently amended) The method of claim 10, wherein Xaa²
~~X2~~ represents Gly.

12. (previously presented) The method of claim 10, wherein
the composition comprises a preservative.

13. (previously presented) The method of claim 12, wherein
the composition comprises a surfactant.

14. (previously presented) The method of claim 4, wherein
the method comprises reconstituting a lyophilized composition comprising
the non-naturally occurring polypeptide and preparing the
pharmaceutically acceptable composition prior to administering the
pharmaceutically acceptable composition to the patient.

15. (previously presented) The method of claim 10, wherein
the method comprises reconstituting a lyophilized composition comprising
the non-naturally occurring polypeptide prior to administering the
polypeptide to the patient.